Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs.
Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs.
Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study / Lanini, Simone; Scognamiglio, Paola; Mecozzi, Alessandra; Lombardozzi, Lorella; Vullo, Vincenzo; Angelico, Mario; Gasbarrini, Antonio; Taliani, Gloria; Attili, Adolfo Francesco; Perno, Carlo Federico; De Santis, Adriano; Puro, Vincenzo; Cerqua, Fabio; D'Offizi, Gianpiero; Pellicelli, Adriano; Armignacco, Orlando; Mennini, Francesco Saverio; Siciliano, Massimo; Girardi, Enrico; Panella, Vincenzo; Ippolito, Giuseppe; Mastroianni, Claudio; D'Ettorre, Gabriella; Lichtner, Miriam; Accapezzato, D; GINANNI CORRADINI, Stefano; Mezzaroma, Ivano; members of the Lazio Region HCV treatment, Group; Gentile, Giuseppe. - In: BMC INFECTIOUS DISEASES. - ISSN 1471-2334. - ELETTRONICO. - 18:1(2018), pp. 223-234. [10.1186/s12879-018-3125-6]
Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study
Vullo, Vincenzo;Taliani, Gloria;Attili, Adolfo Francesco;De Santis, Adriano;Mastroianni, Claudio;d'Ettorre, Gabriella;Lichtner, Miriam;Accapezzato, D;Ginanni Corradini Stefano;Mezzaroma Ivano;Gentile Giuseppe
2018
Abstract
Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs.| File | Dimensione | Formato | |
|---|---|---|---|
|
Lanini_Impact-of-new-DAA_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.28 MB
Formato
Adobe PDF
|
1.28 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
